<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1054151198438221&amp;ev=PageView&amp;noscript=1">

It looks like your browser is incompatible with our website.

If you are currently using IE 11 or earlier, we recommend you update to the new Microsoft Edge or visit our site on another supported browser.


Press Releases


HCPengage.com Website Highlights Healthcare Professional (HCP) Preferences & Current Challenges in Medical Marketing

June 22, 2012

The website, sponsored by Reprints Desk and ExL Pharma, features thought leader interviews on sales rep interactions, regulatory compliance, and digital content strategies

Encino, Calif., June 22, 2012– Reprints Desk, Inc., a Derycz Scientific (OTC.BB:DYSC) company, today announced the launch of the content-enriched website www.hcpengage.com. The HCPengage.com website, sponsored by Reprints Desk and ExL Pharma, features video interviews with healthcare professionals and industry thought leaders from The CementBloc, Digitas Health, Epstein Becker Green, and Prolifiq Software, Inc., discussing: 

  • Opinions and preferences for sales rep interactions
  • The impact of scientific journal content
  • Digital content strategies & iPads
  • Off label promotions & Good Promotional Practices
  • Plus a number of other topics

The HCPengage.com website is made possible through sponsorship by Reprints Desk, creators of Article Viewer Mobile App for putting medical reprints on iPads and websites, and ExL Pharma, producer of conferences such as Digital Marketing for Medical Devices, Digital Pharma East and Digital Pharma West. The website was created to further the dialogue related to the peer-reviewed science and interactions between healthcare professionals, patients, sales reps, and life science companies.

For more information, visit www.hcpengage.com.

About Exl Pharma
ExL Pharma, a division of ExL Events, Inc., is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and various markets. Behind our diverse pharmaceutical event portfolio, ExL's experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events designed to exceed the dynamic informational and networking needs of specific audiences and working groups.

About Reprints Desk®
Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions and scientific, technical, and medical (STM) research. Organizations based on intellectual property (IP) choose Reprints Desk because of its collaborative business approach, efficient article supply system and services, and commitment to quality post-sales support. Outsell Inc., an independent analyst and advisory firm, ranked Reprints Desk #1 in the most recent Document Delivery Vendor Scorecard.

About Derycz Scientific®
Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules.  Its subsidiary companies include Reprints Desk, Inc. and Techniques Appliqueés aux Arts Graphiques, S.p.A. (TAAG).  For more information, please visit www.deryczscientific.com.

Forward-Looking Statements
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K. The Company assumes no obligation to update the cautionary information in this release.

Ready to See
Article Galaxy in Action?

Schedule a call with one of our advisors. We will get you
started with a FREE 14-day trial, with no obligation.